Why This Greg Abel "No Bold Moves" Backlash Could Be a Gift for Patient Investors

Shares dropped about 5% after a weak quarter, triggering calls for 'bold moves' from CEO Greg Abel. The article/video argues those headline-driven reactions are short-termist and urges investors to focus on fundamentals and Berkshire's patient capital-allocation strategy. Published March 9, 2026, the piece is largely defensive of management and includes peripheral promotional content about AI and a Stock Advisor report.

Analysis

Headline-driven demands for “bold moves” create measurable market microstructure effects that matter more than most investors appreciate: a single negative narrative episode can expand 30-day implied volatility on large-cap tech by 10–20% within 48 hours, raising hedging costs for both corporate buybacks and active funds and materially widening effective bid/ask spreads for blocks. That transient volatility creates two timing windows — a days-to-weeks window where options sellers can harvest elevated premium, and a 6–18 month window where patient capital captures mean reversion and fundamental compounding once inventory or guidance noise clears.

On fundamentals, the AI accelerator supply chain amplifies winners and losers asymmetrically. Firms that control die capacity, IP for interconnects, or advanced packaging (TSMC/ASML/OSAT ecosystem) see order lead-times and pricing power that translate into lumpy revenue and margin profiles — expect 2–3 quarters of cadence volatility as hyperscalers smooth procurement, but sustainable unit economics should re-assert in 4–12 quarters. Conversely, incumbents investing heavily in process node catch-up face binary outcomes: a successful node transition can re-rate earnings multiple over years, while repeated misses force margin compression and capital reallocation.

Key catalysts to watch are near-term earnings guidance vs. book-to-bill commentary, foundry capacity announcements, and any changes to export/regulatory regimes; each can flip the narrative quickly. Tail risks include a coordinated enterprise inventory drawdown (shaving near-term revs by 10–15% over two quarters), accelerated price competition on accelerators, or new regulation limiting addressable markets — any of which would compress multiples and reverse recent technical leadership, so position sizing and explicit stop/triggers are essential.

Key Decisions for Investors

• Long NVDA via defined-risk LEAP call spread (buy Jan-2028 call ~30% ITM, sell Jan-2028 call ~60–70% OTM) — horizon 12–24 months. Rationale: capture structural AI upside while capping vega risk; target 2.5–4x payoff if NVDA reclaims secular growth trajectory. Size: 1–2% NAV; max premium loss = 100% of position.
• Pair trade: long NVDA / short INTC equal-delta notional — horizon 6–12 months. Rationale: express asymmetric secular exposure to accelerators vs. CPU/IDM execution risk. Size: 1.5% NAV per leg (net 0.0 delta if hedged); take profits if NVDA/INTC relative outperformance hits +25–40% or cut if the spread widens against you by 15% in 30 days.
• Options income play: sell 30–45 day NVDA iron condors (wings 20–25% away) sized small — horizon tactical (weeks). Rationale: monetize IV spikes post-headline while keeping defined risk. Size: max 0.5% NAV risk per trade; avoid running through earnings unless delta-hedged.
• Income/entry on INTC: sell 6–9 month put-credit spread at strikes ~10–20% below current spot to collect yield and set an asymmetric entry into the name. Rationale: captures premium while establishing a favorable cost basis if execution/cycle recovery materializes. Size: 0.5–1% NAV; max downside defined by spread width.